Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 3/20 | 0.55 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.55 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10224058 | 0.91 | EPHX1 (0.60) | ANPEPRNPEPDNPEPRAB9ASMN1; SMN2 | |
| SCHEMBL7750816 | 0.91 | ANPEP (0.48) | ANPEPRNPEPDNPEPRAB9ASMN1; SMN2 | |
| SCHEMBL11151073 | 0.89 | ANPEP (0.47) | ANPEPRNPEPDNPEPRAB9ASMN1; SMN2 | |
| SCHEMBL7751971 | 0.87 | ANPEP (0.50) | ANPEPRNPEPDNPEPRAB9ASMN1; SMN2 | |
| SCHEMBL12787079 | 0.85 | EPHX1 (0.57) | ANPEPRNPEPDNPEPRAB9ASMN1; SMN2 | |
| SCHEMBL9699575 | 0.85 | ANPEP (0.48) | ANPEPRNPEPDNPEPRAB9ASMN1; SMN2 | |
| SCHEMBL28409872 | 0.85 | ANPEP (0.44) | ANPEPRNPEPDNPEPRAB9ASMN1; SMN2 | |
| SCHEMBL11168376 | 0.84 | EPHX1 (0.53) | ANPEPRNPEPDNPEPSMN1; SMN2GAA | |
| Hydrochloric Acid SCHEMBL8718980 | 0.84 | ANPEP (0.52) | ANPEPRNPEPDNPEPRAB9ASMN1; SMN2 | |
| SCHEMBL14521021 | 0.83 | EPHX1 (0.73) | SMN1; SMN2EPHX1MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3875510-A1 | METHOD FOR PRODUCING AN ETHER ESTOL | Covestro Deutschland AG (DE) | 2021-09-08 | — | — | EP | claimed |
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-07-20 | — | — | US | disclosed |
| US-11643397-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2021-11-11 | — | — | US | disclosed |
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2020-05-21 | — | — | US | disclosed |
| US-10336711-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180305323-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2018-10-25 | — | — | US | disclosed |
| US-10035779-B2 | Prolyl hydroxylase inhibitors | GlaxoSmithKline, LLC (US) | 2018-07-31 | — | — | US | disclosed |
| EP-2037922-B9 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20160297772-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-10-13 | — | — | US | disclosed |
| US-20140024666-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-01-23 | — | — | US | disclosed |
| EP-2037922-B1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-01-22 | — | — | EP | disclosed |
| US-8557834-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-8324208-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-12-04 | — | — | US | disclosed |
| EP-1279667-B1 | PROCESS FOR PRODUCING 1,3-DIALKYL-2-IMIDAZOLIDINONE COMPOUND | MITSUI CHEMICALS INC (JP) | 2010-10-27 | — | — | EP | disclosed |
| US-20100113444-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-05-06 | — | — | US | disclosed |
| US-6861534-B2 | Process for producing 1,3-dialkyl-2-imidazolidinone compound | MITSUI CHEMICALS, INC. (JP) | 2005-03-01 | — | — | US | disclosed |
| EP-1279667-A1 | PROCESS FOR PRODUCING 1,3-DIALKYL-2-IMIDAZOLIDINONE COMPOUND | Mitsui Chemicals, Inc. (JP) | 2003-01-29 | — | — | EP | disclosed |
| US-20030009035-A1 | Process for producing 1,3-dialkyl-2-imidazolidinone compound | MITSUI CHEMICALS, INC. (JP) | 2003-01-09 | — | — | US | disclosed |
| US-6498164-B1 | SUCH AS 1,3-DIBENZYL-5-(PHENYL- OR 2-THIENYL-ACETYL)BARBI-TURIC ACID; MALIGNANT HYPERCALCEMIA, OSTEOLYTIC DISEASES SUCH AS PAGET'S DISEASE, OSTEOPOROSIS, ARTICULAR RHEUMATISM OCCURRING IN KNEES, SHOULDERS, JOINTS | AVENTIS PHARMA S.A. (FR) | 2002-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024666-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | ANPEP 455/4885RNPEP 523/4885DNPEP 160/4885 |
| US-20030009035-A1 | Process for producing 1,3-dialkyl-2-imidazolidinone compound | PIGS, DEK, B2M | ANPEP 938/4885RNPEP 2025/4885DNPEP 870/4885 |
| US-11643397-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | ANPEP 455/4885RNPEP 523/4885DNPEP 160/4885 |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | ANPEP 455/4885RNPEP 523/4885DNPEP 160/4885 |
| US-20100113444-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | ANPEP 517/4885RNPEP 553/4885DNPEP 162/4885 |
| US-10336711-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | ANPEP 455/4885RNPEP 523/4885DNPEP 160/4885 |
| US-20160297772-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | ANPEP 455/4885RNPEP 523/4885DNPEP 160/4885 |
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | ANPEP 455/4885RNPEP 523/4885DNPEP 160/4885 |
| US-20180305323-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | ANPEP 455/4885RNPEP 523/4885DNPEP 160/4885 |
| US-10035779-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | ANPEP 455/4885RNPEP 523/4885DNPEP 160/4885 |
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | ANPEP 455/4885RNPEP 523/4885DNPEP 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.